D3 Bio’s debut with $200M series A highlights China’s fast-track to global stage

The latest in a growing list of Chinese biopharma “money magnets,” D3 Bio has made its official launch with a strategy that reflects emerging trends in the sector, which include moving away from me-too pipelines, relying on domestic investors to finance growth, and looking outward toward the global market.

Oncology- and immunology-focused D3 Bio unveiled a $200 million series A round Tuesday backed by a syndicate of investors including Boyu Capital, Matrix Partners China, Sequoia Capital China, Temasek, and WuXi AppTec’s Corporate Venture Fund. ...